Dr Reddy's Q3 net rises 16 times
Dr Reddy's quarterly profit rose nearly 16 times over the year-ago period.
Dr Reddy's Laboratories Ltd said on Tuesday that its quarterly profit rose nearly 16 times over the year-ago period as the Indian drug maker bounced off a low base and saved on research costs.
The Hyderabad-based company, India's only New York-listed drug maker, said net profit for the quarter to December, based on US accounting standards, was Rs 628 million ($14 million), compared with Rs 40 million a year earlier.
A Reuters poll of 10 analysts had projected the firm to post a net profit of Rs 462 million in the fiscal third quarter.
Dr Reddy's, an early Indian entrant into the US generics market, has been through a rough patch over the past three years. During that time, it's had no big drug launches to fill the hole caused when its exclusive rights to sell a version of Eli Lilly & Co's blockbuster Prozac anti-depressant ended in the financial year ending March 2002.
The company had been bogged down by high research-and-development costs for both its generic and new drug programmes. It entered into cost-sharing deals with venture capitalists last year in a bid to reduce its burden.
Dr Reddy's shares gained 15 per cent during the quarter, outperforming a 1.2 per cent rise in the healthcare index during the same period.
Get Current Updates on India News, Lok Sabha Election 2024 live, Infosys Q4 Results Live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.